References
- Adams JM, Cory S (1998): The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322–1326. [INFOTRIEVE], [CSA]
- Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K (1998): Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91: 1700–1705. [INFOTRIEVE], [CSA]
- Cai X, Wang GJ, Zai Y, et al. (1997): Analysis of efficacy of matrine injection in treatment of chronic hepatitis B. Acad J Second Military Med Univ 18: 47–49. [CSA]
- Daley G, Ven Etten R, Baltimore D (1990): Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830. [INFOTRIEVE], [CSA]
- Dhut S, Champlin T, Young BD (1990): BCR/ABL and ABL proteins: Biochemical characteization and localization. Leukemia 4: 745–750. [INFOTRIEVE], [CSA]
- Dorsey JF, Jove R, Kraker AJ, Wu J (2000): The pyrido[2,3-d.]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60: 3127–3131. [INFOTRIEVE], [CSA]
- Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996): Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 2: 561–566. [INFOTRIEVE], [CROSSREF], [CSA]
- Gesbert F, Griffin JD (2000): Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96: 2269–2276. [INFOTRIEVE], [CSA]
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001): In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999–2007. [INFOTRIEVE], [CROSSREF], [CSA]
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002): Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645–652. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Liu XS, Jiang J (2005): Alterations in tyrosine protein phosphorylation induced by matrine in leukemia cells. Pharm Biol 43: 624–629. [CSA]
- Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990): Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082. [INFOTRIEVE], [CSA]
- Morgan MA, Dolp O, Reuter CW (2001): Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97: 1823–1834. [INFOTRIEVE], [CROSSREF], [CSA]
- Mosmann T (1983): Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Immunol Methods 65: 55–63. [CROSSREF], [CSA]
- Nimmanapalli R, Bali P, O'Bryan E, Fuino L, Guo F, Wu J, Houghton P, Bhalla K (2003): Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 63: 7950–7958. [INFOTRIEVE], [CSA]
- Niu KZ (1997): Pharmacology and clinical application of Sophora flavescents.. Int J Oriental Med 22: 75–81. [CSA]
- Nowell PC, Hungerford DA (1960): A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497–1499. [CSA]
- Ray S, Bullock G, Nunez G, Tang C, Ibrado AM, Huang Y, Bhalla K (1996): Enforced expression of Bcl-xS induces differentiation and sensitizes CML-blast crisis K562 cells to Ara-C mediated differentiation and apoptosis. Cell Growth Differ 7: 1617–1623. [INFOTRIEVE], [CSA]
- Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA (2002): Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99: 10700–10705. [INFOTRIEVE], [CROSSREF], [CSA]
- Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000): Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 96: 3195–3199. [INFOTRIEVE], [CSA]
- Wang S, Guo CY, Castillo A, Dent P, Grant S (1998): Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 56: 635–644. [INFOTRIEVE], [CROSSREF], [CSA]
- Woessmann W, Miveschi NF (2001): Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp Cell Res 264: 193–200. [INFOTRIEVE], [CROSSREF], [CSA]
- Xia Z, Dickens M, Raingeaud J, Davis RJ (1995): Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326–1331. [INFOTRIEVE], [CSA]
- Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, Liu BZ, He YJ (2001): Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res 25: 793–800. [INFOTRIEVE], [CROSSREF], [CSA]